Fx-1006A
- Generic Name
- Fx-1006A
- Drug Type
- Small Molecule
- Background
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
- Indication
Investigated for use/treatment in amyloidosis.
Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
- Conditions
- Mild Hepatic DysfunctionModerate Hepatic Dysfunction
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01358565
- Locations
- πΏπ¦
Pfizer Investigational Site, Newton Park, Port Elizabeth, South Africa
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00791492
- Locations
- π΅πΉ
Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Portugal
π¦π·FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Argentina
πΈπͺUmea University Hospital, Umea, Sweden
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00694161
- Locations
- πΊπΈ
Emory University School of Medicine, Atlanta, Georgia, United States
πΊπΈUniversity of Chicago, Chicago, Illinois, United States
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
- Conditions
- Transthyretin-associated Amyloidosis With Polyneuropathy
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00630864
- Locations
- π«π·
CHU de Bicetre, Paris, France
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States
π©πͺUniversitatsklinikum Munster, Transplant Hepatology, Munster, Germany
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00409175
- Locations
- π΅πΉ
Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Norte, Portugal
πΊπΈMGH Neuropathy Laboratory, Boston, Massachusetts, United States
π¦π·FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Buenos Aires Province, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.